Group B *Streptococcus* in surgical site and non-invasive bacterial infections worldwide: A systematic review and meta-analysis☆

Simon M. Collin[a,*], Nandini Shetty[a], Rebecca Guy[a], Victoria N. Nyaga[b], Ann Bull[c], Michael J. Richards[c], Tjallie I.I. van der Kooi[d], Mayke B.G. Koek[d], Mary De Almeida[e], Sally A. Roberts[e], Theresa Lamagni[a]

[a] *Healthcare-Associated Infection and Antimicrobial Resistance (HCAI & AMR) Division, National Infection Service, Public Health England, London, UK*
[b] *SCIENSANO, Unit of Cancer Epidemiology, Belgian Cancer Centre, Brussels, Belgium*
[c] *VICNISS Coordinating Centre, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia*
[d] *Department of Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands*
[e] *Microbiology Department, LabPlus, Auckland District Health Board, Auckland, New Zealand*

A B S T R A C T

Objectives: The epidemiology of disease caused by group B *Streptococcus* (GBS; *Streptococcus agalactiae*) outside pregnancy and the neonatal period is poorly characterized. The aim of this study was to quantify the role of GBS as a cause of surgical site and non-invasive infections at all ages.
Methods: A systematic review (PROSPERO CRD42017068914) and meta-analysis of GBS as a proportion (%) of bacterial isolates from surgical site infection (SSI), skin/soft tissue infection (SSTI), urinary tract infection (UTI), and respiratory tract infection (RTI) was conducted.
Results: Seventy-four studies and data sources were included, covering 67 countries. In orthopaedic surgery, GBS accounted for 0.37% (95% confidence interval (CI) 0.08–1.68%), 0.87% (95% CI 0.33–2.28%), and 1.46% (95% CI 0.49–4.29%) of superficial, deep, and organ/space SSI, respectively. GBS played a more significant role as a cause of post-caesarean section SSI, detected in 2.92% (95% CI 1.51–5.55%), 1.93% (95% CI 0.97–3.81%), and 9.69% (95% CI 6.72–13.8%) of superficial, deep, and organ/space SSI. Of the SSTI isolates, 1.89% (95% CI 1.16–3.05%) were GBS. The prevalence of GBS in community and hospital UTI isolates was 1.61% (1.13–2.30%) and 0.73% (0.43–1.23%), respectively. GBS was uncommonly associated with RTI, accounting for 0.35% (95% CI 0.19–0.63%) of community and 0.27% (95% CI 0.15–0.48%) of hospital RTI isolates.
Conclusions: GBS is implicated in a small proportion of surgical site and non-invasive infections, but a substantial proportion of invasive SSI post-caesarean section.

Introduction

Streptococcus agalactiae (group B *Streptococcus*, GBS) is implicated in a range of clinical presentations, including skin and soft tissue infections (SSTI) and urinary tract infections (UTI) (Kerneis et al., 2017; Chaiwarith et al., 2011; Falagas et al., 2006). GBS disease in adults is of growing clinical and public health concern (Bjornsdottir et al., 2016; Lamagni et al., 2013; Skoff et al., 2009), and the increasing prevalence of risk factors for GBS disease including old age and diabetes (Ballard et al., 2016; Camuset et al., 2015; Lefebvre et al., 2007; Huang et al., 2006) implies considerable health and social care costs (Badia et al., 2017; Kennedy et al., 2013; Ciani et al., 2013; Allegranzi et al., 2011). The advent of vaccines to prevent neonatal GBS disease raises the possibility of preventing GBS disease in other patient groups (Kim et al., 2017; Heath et al., 2017; Vekemans et al., 2018). Whilst the worldwide burden of maternal and infant GBS disease has been quantified (Madrid et al., 2017; Le Doare et al., 2017; Russell et al., 2017a; Hall et al., 2017; Tann et al., 2017; Kohli-Lynch et al., 2017; Bianchi-Jassir et al., 2017; Russell et al., 2017b; Seale et al., 2017a; Seale et al., 2017b), the burden of other forms of GBS disease is unknown (Le Doare and Heath, 2013).

The aim of this systematic review was to quantify the role of GBS as a cause of surgical site, healthcare-associated, and non-invasive bacterial infections. All types of surgical site infection (SSI) were included, namely superficial, deep, and organ/space, along with catheter-associated UTI and ventilator-associated pneumonia (VAP). For other types of infection, 'non-invasive' was defined by excluding infections where GBS was detected at a sterile site. Infections where GBS was detected in urine were included because UTIs are relatively common in the population and the overall proportion attributable to GBS is unquantified.

Methods

This review was registered with PROSPERO (CRD42017068914). Scoping reviews showed that the incidence of GBS has rarely been reported; hence, the primary outcome was GBS as a proportion of the total number of bacterial isolates for each type of infection.

Searches

The types of infection were not pre-specified, but the search strategy aimed to capture epidemiological studies and surveillance sources of surgical site, healthcare-associated, skin/soft tissue/ wound, urinary tract, and respiratory tract infections (RTI). The following databases and libraries were searched: MEDLINE, Embase, CINAHL, Scopus, Global Health, and Trip (including DARE and Cochrane). Full search terms are provided as **Supplementary Material**. In brief, medical subject heading (MeSH) search terms for "Bacterial Infections", "Microbial Sensitivity Tests", "Cross Infection", "Soft Tissue Infections", "Urinary Tract Infections", "Respiratory Tract Infections", "Wound Infections", or "*Streptococcus agalactiae*" were used in conjunction with text word terms for healthcare-associated, surgical, or community infection or group B/haemolytic streptococcal infection. Studies with title words indicating a focus on non-surgical invasive infection (bloodstream, endocarditis, meningitis, sepsis, or bacteraemia) were excluded. The search was restricted to publication dates from January 1, 2000 to July 5th 2017 and to studies in humans. There was no language restriction.

Screening and extraction

Citations identified by the search were imported into EndNote (EndNote X8; Clarivate Analytics, Boston, MA, USA) for de-duplication, and then imported into EPPI-Reviewer (EPPI-Reviewer 4; EPPI-Centre Software; Social Science Research Unit, UCL Institute of Education, London, UK) for further de-duplication. One reviewer (SC) conducted a first screen by title and abstract; two reviewers (SC and TL) then conducted a second screen by title and abstract independently and in parallel, and disagreements were resolved with a third reviewer (NS). Full texts of all articles identified in the second screen by title and abstract were retrieved. These were screened for final inclusion by one reviewer (SC) concurrently with data extraction. A second reviewer (TL) independently checked inclusion/exclusion and data extraction from a randomly selected sample (10%) of full texts.

Study selection (PRISMA flow diagram)

Figure 1. Study selection (PRISMA flow diagram).

Quality assessment

The methodological quality of included studies was rated by two reviewers (SC 100%, TL 10%) using a nine-item quality assessment tool adapted from the National Institutes of Health Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies (see **Supplementary Material**). The adaptation allowed for the assessment of the quality of data from surveillance systems and studies based on routine laboratory data, which comprised the majority of the included data sources. Each source/study was rated as being of 'good', 'fair', or 'poor' quality. Data were not extracted from sources/studies that were rated 'poor'.

Other data sources

If a study did not report data at the level of detail required for the meta-analyses, e.g. pathogens reported solely as '*Streptococcus spp*' or 'Other', or aggregated data for all types of surgical site infection, the authors were contacted to request data. If unpublished data were provided that superseded data reported in retrieved texts, the most relevant or recent reference was retained as the citation or an additional reference was included as 'identified through other sources'. Three institutions that publish routine surveillance data were identified prior to the review as potential sources of data: Public Health England (PHE), the European Centre for Disease Prevention and Control (ECDC), and the US Centers for Disease Control and Prevention (CDC).

Meta-analysis

Binomial-normal random-effects meta-analysis of GBS as a proportion of all isolated microorganisms was performed in Stata Release 13, 2013 (StataCorp., College Station, TX, USA) using 'metaprop_one' (Nyaga et al., 2014). In this approach, the binomial distribution is used to model within-study variability, and the normal distribution is used to model the random effects. Between-study heterogeneity was estimated as τ^2, and evidence of heterogeneity was tested by likelihood ratio (LR) test comparing random- and fixed-effects models. The proportion of overall heterogeneity attributable to between-study variance was quantified using a formulation of the I^2 statistic for binary variables (Zhou and Dendukuri, 2014). Prediction intervals were estimated to show the expected prevalence of GBS taking into account between-study variability (IntHout et al., 2016; Nagashima et al., 2018). Meta-analysis defaulted to fixed-effects if three or fewer studies were included. Subgroup analyses specified a priori were: age group (neonatal, child, adult, elderly); surgical specialty, type of SSI (superficial incisional, deep incisional, or organ/space) (Owens and Stoessel, 2008); and putative origin of infection (community, hospital, device/procedure).

Role of the funding source

The funder of the study (Pfizer Inc.) had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to the data in the study and final responsibility for the decision to submit this paper.

Results

Database searches identified 10 879 references (Figure 1); 349 were retained for full-text review, of which 63 were included for data extraction and meta-analysis. Agreement between the two reviewers at the title/abstract and full-text screening stages was 92% (26/340) and 91% (32/35), respectively. The 63 full-text references included two relating to data sources identified prior to the review, namely CDC (SSI, UTI, and RTI data) (Weiner et al. (2016)) and PHE (SSI data) (Elgohari et al., 2017). ECDC SSI (European Centre for Disease Prevention and Control (ECDC), 2016), ECDC point prevalence survey (PPS) of healthcare-associated infections (HAI) in acute hospitals (European Centre for Disease Prevention and Control (ECDC), 2013), and ECDC intensive care unit (ICU) HAI data (European Centre for Disease Prevention and Control (ECDC), 2017) are summarized in reports, but no published record could be found for PHE UTI data. These four additional data sources (three ECDC, one PHE) were included as 'identified prior to review'; a further seven 'additional records/data sources' were identified during full-text screening (Bouza et al., 2001a; Canadian Antimicrobial Resistance Alliance (CARA), 2016; Lee et al., 2004; Morris et al., 2015; Santé publique France, 2016; Stapleton et al., 2007; Garau et al., 2013) (Figure 1). The total number of included studies and data sources (hereafter referred to as 'sources') was 74 (Table 1, Figure 1), representing 67 countries (Figure 2); 77% (57/74) were rated good quality and 23% (17/74) fair quality (83% agreement) (see **Supplementary Material**).

Types of infection

The six foci of infection that emerged from the review were surgical site (17 sources), skin and soft tissue (14 sources), urinary (42 sources), respiratory (17 sources), ear (two sources), and eye (six sources). SSI were defined in the majority of sources according to

Table 1
Studies/sources contributing data to the meta-analyses for each type of infection.

Type of infection	Number of studies/ data sources[a]	Number of countries	Quality rating			Total number of estimates included[b]	Total number of isolates/ infections	Total number of GBS isolates/ infections
			Good	Fair	Poor			
Surgical site	17	38	14 (82.4%)	3 (17.6%)	0 (0.0%)	87	224 544	2634
Skin and soft tissue	14	60	10 (71.4%)	4 (28.6%)	0 (0.0%)	27	181 575	3842
Urinary	42	45	32 (76.2%)	10 (23.8%)	0 (0.0%)	57	2 820 252	49 609
Respiratory	17	38	12 (70.6%)	5 (27.8%)	0 (0.0%)	23	39 181	171
Ear	2	1	2 (100.0%)	0 (0.0%)	0 (0.0%)	2	264	0
Eye	6	9	3 (50.0%)	3 (50.0%)	0 (0.0%)	6	5981	30

GBS, group B *Streptococcus*.
[a] Fourteen of the 74 sources provided data on more than one type of infection.
[b] Some sources contributed multiple estimates of the prevalence of GBS, e.g. from several settings, cohorts, countries, or time periods.

Figure 2. Countries represented in included studies.

CDC/National Healthcare Safety Network (NHSN) criteria, i.e. superficial incisional (involving only skin and subcutaneous tissue of the incision), deep incisional (involving deep soft tissue of the incision, e.g. fascia/muscle), and organ/space (involving any part of the anatomy deeper than the fascial/muscle layers, e.g. organ, breast, spinal or intracranial abscess, bone, joint or bursa, myo-, peri- or endocardium, intra-abdominal, arterial or venous) (Owens and Stoessel, 2008; Horan et al., 2008). UTI case definitions varied more widely, but typically required $>10^5$ CFU/ml or $>10^4$ CFU/ml with symptoms or leukocyturia. Community- vs. healthcare-associated UTI and RTI were differentiated either by time since admission (<48 h for community), specimen source (primary vs. secondary or tertiary care), or if reported as healthcare-associated, e.g. catheter-associated urinary tract infection (CAUTI) and VAP. There was considerable variation across sources of SSTI data: some focused on complicated SSTI (cSSTI), defined as requiring surgical intervention, involving deeper soft tissue or occurring in an immunocompromised patient (Montravers et al., 2013); some included wound and surgical site infection; some included isolates from a range of specimens (including blood). The proportions of studies that accounted for polymicrobial infections, i.e. where the denominator was the total number of isolates, rather than reporting only one isolate per infection, were 88% (15/17) for SSI, 50% (7/14) for SSTI, 60% (25/42) for UTI, and 65% (11/17) for RTI. Fourteen of the 74 sources provided data on more than one type of infection, and some contributed multiple estimates of the prevalence of GBS to each meta-analysis, e.g. from several settings, cohorts, countries, or time periods.

Surgical site infection

Seventeen sources of SSI data were included (Weiner et al., 2016; Elgohari et al., 2017; European Centre for Disease Prevention and Control (ECDC), 2016; Morris et al., 2015; Santé publique France, 2016; Cossin et al., 2015; Deptula et al., 2017; Fong et al., 2015; Jeong et al., 2013; Jodra et al., 2006; Kim et al., 2012; Phu et al., 2016;

Rennert-May et al., 2016; Sabra and Abdel-Fattah, 2012; Song et al., 2012; Worth et al., 2015; Mannien et al., 2007), six of which were disaggregated by type of SSI (Elgohari et al., 2017; European Centre for Disease Prevention and Control (ECDC), 2016; Morris et al., 2015; Jodra et al., 2006; Worth et al., 2015; Mannien et al., 2007). GBS represented 0.73% (95% confidence interval (CI) 0.40–1.34%) of SSI isolates from all types of surgery (Table 2). The highest prevalence of GBS was in obstetrics/gynaecology (including caesarean section): GBS represented 3.50% (95% CI 2.14–5.67%) of isolates of any SSI type, 3.87% (95% CI 1.82–8.00%) of superficial SSI isolates, 3.80% (95% CI 1.82–7.76%) of deep incisional isolates, and 10.5% (95% CI 6.86–15.7%) of organ/space isolates (Table 2). For caesarean section, the prevalence of GBS among all SSI isolates was 3.49% (95% CI 1.99–6.06%), increasing from 2.92% (95% CI 1.51–5.55%) for superficial and 1.93% (95% CI 0.97–3.81%) for deep SSI to 9.69% (95% CI 6.72–13.8%) for organ/space SSI (between-subgroups $p < 0.01$) (Figure 3). A similar trend towards a higher prevalence of GBS in invasive compared with superficial SSI was seen for orthopaedic surgery (Figure 4), but not for abdominal or cardiac surgery (Table 2).

GBS accounted for 2.40% (95% CI 1.89–3.05%) of isolates from SSI after vascular surgery, 1.23% (95% CI 0.84–1.79%) of breast surgery SSI isolates, and 1.14% (95% CI 0.51–2.53%) of orthopaedic surgery SSI isolates (Table 2, **Supplementary Material** Figures). For other types of surgery where more than one data source was identified (abdominal, cardiac, neuro/cranial, prostate), the prevalence of GBS was ≤0.25%. Data were available from only a single source (CDC) (Weiner et al., 2016) for kidney, neck, and transplant surgery. Of 18 subgroup meta-analyses by surgical category and SSI type (Table 2), 10 had evidence ($p \leq 0.01$) of between-study heterogeneity, representing 10–25% of variance in prevalence estimates.

Skin and soft tissue infection

Fourteen sources of data on SSTI were included (European Centre for Disease Prevention and Control (ECDC), 2013; Canadian

Table 2
Streptococcus agalactiae as a percentage of surgical site infection (SSI) isolates.

Surgical category	Superficial incisional			Deep incisional			Organ/space			All types of SSI		
	Estimates included, n	Pooled % prevalence (95% CI)	I^2 (p-Value)	Estimates included, n	Pooled % prevalence (95% CI)	I^2 (p-Value)	Estimates included, n	Pooled % prevalence (95% CI)	I^2 (p-Value)	Estimates included, n	Pooled % prevalence (95% CI)	I^2 (p-Value)
Various (not specified)										5	0.74 (0.64–0.86) $\tau^2 = 0.00$	0.0% ($p = 1.00$)
Abdominal[a]	15	0.23 (0.05–1.08) $\tau^2 = 1.92$	11.2% ($p < 0.01$)	12	0.37 (0.08–1.76) $\tau^2 = 1.43$	15.5% ($p < 0.01$)	12	0.19 (0.04–0.84) $\tau^2 = 1.40$	11.7% ($p = 0.01$)	19	0.25 (0.10–0.63) $\tau^2 = 1.03$	16.2% ($p < 0.01$)
Breast										4	1.23 (0.84–1.79) $\tau^2 = 0.00$	0.0% ($p = 1.00$)
Cardiac[b]	11	0.17 (0.07–0.41) $\tau^2 = 0.00$	0.0% ($p = 1.00$)	9	0.18 (0.03–0.96) $\tau^2 = 1.23$	4.1% ($p = 0.10$)	7	0.18 (0.05–0.73) $\tau^2 = 0.00$	0.0% ($p = 1.00$)	12	0.22 (0.07–0.69) $\tau^2 = 1.23$	12.3% ($p < 0.01$)
Obs/Gyn[c]												
Inc. C-section	3	3.87 (1.82–8.00) $\tau^2 = 0.39$	–	2	3.80 (1.82–7.76)	–	3	10.5 (6.86–15.7) $\tau^2 = 0.00$	–	5	3.50 (2.14–5.67) $\tau^2 = 0.30$	85.6% ($p < 0.01$)
Exc. C-section	3	3.12 (1.41–6.78) $\tau^2 = 0.00$	–	2	8.11 (2.64–22.3)	–	2	6.06 (1.52–21.2)	–	3	3.94 (2.30–6.67) $\tau^2 = 0.00$	–
Caesarean section	13	2.92 (1.51–5.55) $\tau^2 = 0.41$	27.6% ($p < 0.01$)	7	1.93 (0.97–3.81) $\tau^2 = 0.00$	0.0% ($p = 1.00$)	7	9.69 (6.72–13.8) $\tau^2 = 0.00$	0.13% ($p = 0.50$)	15	3.49 (1.99–6.06) $\tau^2 = 0.31$	27.2% ($p < 0.01$)
Kidney										1	0.00 (0.00–1.33)	–
Neck[d]										1	0.47 (0.08–2.62)	–
Neuro/cranial[e]										4	0.20 (0.09–0.49) $\tau^2 = 0.00$	0.0% ($p = 1.00$)
Orthopaedic[f]	13	0.37 (0.08–1.68) $\tau^2 = 1.74$	14.3% ($p < 0.01$)	12	0.87 (0.33–2.28) $\tau^2 = 0.78$	25.4% ($p < 0.01$)	11	1.46 (0.49–4.29) $\tau^2 = 1.20$	23.5% ($p < 0.01$)	17	1.14 (0.51–2.53) $\tau^2 = 1.14$	45.3% ($p < 0.01$)
Prostate										2	0.00 (0.00–0.08)	–
Transplant[g]										1	0.25 (0.07–0.89)	–
Vascular[h]										4	2.40 (1.89–3.05) $\tau^2 = 0.00$	0.0% ($p = 1.00$)
All types	52	0.66 (0.31–1.40) $\tau^2 = 0.57$	12.2% ($p < 0.01$)	40	0.66 (0.24–1.84) $\tau^2 = 0.93$	16.2% ($p < 0.01$)	39	1.32 (0.52–3.29) $\tau^2 = 0.86$	25.0% ($p < 0.01$)	87	0.73 (0.40–1.34) $\tau^2 = 0.77$	25.3% ($p < 0.01$)

CI, confidence interval; Inc., including; Exc., excluding.

[a] Abdominal surgery includes appendectomy, bile duct, liver, or pancreatic surgery, gallbladder surgery, colon surgery, gastric surgery, herniorrhaphy, small and large bowel surgery, spleen surgery, and rectal surgery.

[b] Cardiac surgery includes coronary artery bypass graft with chest incision with or without donor incision, pacemaker surgery, and thoracic surgery.

[c] Obstetric and gynaecologic (Obs/Gyn) surgery includes abdominal hysterectomy, ovarian surgery, and vaginal hysterectomy.

[d] Neck surgery includes thyroid and/or parathyroid surgery.

[e] Neurological and cranial surgery includes craniotomy and ventricular shunt.

[f] Orthopaedic surgery includes open reduction of fracture, hip prosthesis, knee prosthesis, limb amputation, spinal fusion, refusion of spine, and laminectomy.

[g] Transplant surgery includes heart, kidney, and liver.

[h] Vascular surgery includes abdominal aortic aneurysm repair, shunt for dialysis, carotid endarterectomy, and peripheral vascular bypass surgery.

Figure 3. Prevalence of *Streptococcus agalactiae* in isolates from surgical site infection (SSI) after caesarean section (by type of SSI).

Antimicrobial Resistance Alliance (CARA), 2016; Garau et al., 2013; Jodra et al., 2006; Heizmann et al., 2013; Jaaskelainen et al., 2016; Jones et al., 2003; Li et al., 2016; Merritt et al., 2013; Mir et al., 2011; Moet et al., 2007; Ray et al., 2013; Zhanel et al., 2010; Behzadnia et al., 2014). The overall prevalence of GBS in SSTI isolates was 1.89% (95% CI 1.16–3.05%) (Table 3). The pooled prevalence of GBS was lower in cSSTI (1.02%, 95% CI 0.48–2.15%) than in sources that did not focus on cSSTI (3.05%, 95% CI 2.00–4.62%) (between-subgroups $p = 0.01$) (Figure 5). Sources that included SSI in their definition of SSTI yielded a lower prevalence (1.62%, 95% CI 1.00–2.59%) than those that did not include SSI (3.06%, 95% CI 1.58–5.84%), but unsupported statistically ($p = 0.19$). One community-based study of omphalitis in Pakistan reported GBS in 10.1% (95% CI 7.79–12.9%) of 583 isolates from umbilical stump purulent secretions (Mir et al., 2011). There was strong evidence ($p < 0.01$) in each subgroup of between-study heterogeneity, contributing a high proportion ($I^2 = 60$–80%) of variance in pooled estimates. GBS prevalence in SSTI isolates from children (excluding neonatal omphalitis) was 1.05% (95% CI 0.15–7.09%), compared with 1.68% (95% CI 0.58–4.78%) in studies that included only adults, but this difference was unsupported by evidence of between-subgroup heterogeneity ($p = 0.65$).

Urinary tract infection

Forty-two sources reporting GBS in UTI were included (Weiner et al., 2016; European Centre for Disease Prevention and Control (ECDC), 2013; European Centre for Disease Prevention and Control (ECDC), 2017; Bouza et al., 2001a; Lee et al., 2004; Jodra et al., 2006; Phu et al., 2016; Sabra and Abdel-Fattah, 2012; Zhanel et al., 2010; Behzadnia et al., 2014; Agodi et al., 2013; Alvarez Lerma et al., 2005; Andreu et al., 2005; Bauserman et al., 2013; Bouza et al.,

2001b; Brabazon et al., 2012; Choi et al., 2016; Greenhow et al., 2014; Guerreiro et al., 2012; Hanna-Wakim et al., 2015; Hayami et al., 2013; Hedin et al., 2002; Hooton et al., 2013; Karlowsky et al., 2011; Kazemier et al., 2014; Kiffer et al., 2007; Kronenberg et al., 2011; Laupland et al., 2007; Lee et al., 2011; Magliano et al., 2012; Malmartel and Ghasarossian, 2016; Matsumoto et al., 2011; Monsen et al., 2014; Moulton et al., 2017; Rodriguez et al., 2005; Sorlozano et al., 2014; Zajac-Spychala et al., 2016; Naber et al., 2008). GBS was found in 1.09% (95% CI 0.77–1.54%) of UTI isolates, with a higher prevalence for community (1.61%, 95% CI 1.13–2.30%) than hospital UTI (0.72%, 95% CI 0.43–1.22%) (between-subgroups $p = 0.01$) (Table 4, Figure 6). The prevalence was no higher in female-only community cohorts (1.51%, 95% CI 0.87–2.62%) than for both sexes combined (Table 4). GBS accounted for a low proportion of CAUTI isolates (0.26%, 95% CI 0.24–0.29%) (Figure 7). The one study that reported a high prevalence of GBS in CAUTI isolates (8.33%, 95% CI 1.03–27.0%) was in a cohort of women who had undergone caesarean section (Moulton et al., 2017). Between-study heterogeneity represented a moderate-to-high proportion of overall variance ($I^2 = 40$–80%, $p < 0.01$) for all meta-analyses except CAUTI (0%).

Respiratory tract infection

Seventeen sources of respiratory tract infection data were included (Weiner et al., 2016; European Centre for Disease Prevention and Control (ECDC), 2013; Canadian Antimicrobial Resistance Alliance (CARA), 2016; Jodra et al., 2006; Phu et al., 2016; Sabra and Abdel-Fattah, 2012; Zhanel et al., 2010; Behzadnia et al., 2014; Agodi et al., 2013; Alvarez Lerma et al., 2005; Choi et al., 2016; El-Kholy et al., 2012; Nizami et al., 2006; Varotto et al., 2001; Ba-Saddik et al., 2014; Hanna et al., 2006). The prevalence of GBS in

Figure 4. Prevalence of *Streptococcus agalactiae* in surgical site infection (SSI) isolates after orthopaedic surgery (by type of SSI).

Table 3
Streptococcus agalactiae as a percentage of skin and soft tissue infection (SSTI) isolates.

SSTI definition	Number of estimates included	Pooled % prevalence estimate (95% CI)	I^2 (p-value)
All types	27	1.89 (1.16–3.05); $\tau^2 = 0.76$	70.4% ($p < 0.01$)
Complicated vs. non-specific[a]			
Complicated SSTI (cSSTI)	13	1.02 (0.48–2.15); $\tau^2 = 0.72$	57.4% ($p < 0.01$)
Not focusing on cSSTI	14	3.05 (2.00–4.62); $\tau^2 = 0.32$	65.1% ($p < 0.01$)
Including vs. excluding surgical site infection (SSI)			
Including SSI	17	1.62 (1.00–2.59); $\tau^2 = 0.37$	60.6% ($p < 0.01$)
Excluding SSI	7	3.06 (1.58–5.84); $\tau^2 = 0.57$	78.3% ($p < 0.01$)

CI, confidence interval.

[a] Skin and soft tissue infections are typically defined as complicated when a surgical intervention is required and/or the infection is suspected or confirmed to involve deeper soft tissue such as the fascia and/or muscle layers. SSTI may also be considered complicated when it occurs in an immunocompromised patient or with a complicating comorbidity such as diabetes mellitus, peripheral vascular disease, or peripheral neuropathy.

RTI isolates from community and hospital sources (including VAP) was 0.30% (95% CI 0.17–0.52%) (Table 5, Figure 8). Prevalence was similar for community (0.35%, 95% CI 0.19–0.63%) and hospital RTI (0.27%, 95% CI 0.15–0.48%) (between-subgroups $p = 0.57$). There was evidence of low between-study heterogeneity ($I^2 = 12$–14%) for all subgroups.

Other types of infection

Two sources reported zero GBS isolates from ear infections: paediatric conjunctivitis–otitis syndrome (COS), 0/86 middle ear fluid samples (Bingen et al., 2005); infant otitis media, 0/178 (Husson et al., 2001). Eye infection data were obtained from six studies (Stapleton et al., 2007; Bingen et al., 2005; Goh et al., 2010; Miller, 2017; Morrissey et al., 2004; Truong et al., 2016). Two studies of keratitis reported zero GBS isolates (out of 59 and 241 isolates) (Stapleton et al., 2007; Truong et al., 2016), as did one study of corneal ulcer isolates (0/34) (Goh et al., 2010). Two studies of mixed ocular infections reported GBS prevalence of 0.62% (29/4649) (Miller, 2017) and 0.19% (1/532) (Morrissey et al., 2004). The paediatric COS study found no GBS in 466 conjunctival exudate isolates (Bingen et al., 2005). Based on the five eye-only sources (Stapleton et al., 2007; Goh et al., 2010; Miller, 2017; Morrissey et al., 2004; Truong et al., 2016), the prevalence of GBS in ocular isolates was 0.16% (95% CI 0.04–0.34%); including COS reduced this to 0.03% (95% CI 0.00–0.30%).

Study/source	Country	Period	GBS	Isolates		Prevalence (95% CI)
SSTI						
Behzadnia (2014)	Iran	2012	0	30		0.00 (0.00, 11.57)
Jodra (2006)	Spain	1997-2006	37	1270		2.91 (2.06, 3.99)
Jodra (2006)	Spain	2007-2016	43	2351		1.83 (1.33, 2.46)
Merritt (2013) - adult	USA	2010	8	218		3.67 (1.60, 7.10)
Merritt (2013) - child	USA	2010	1	65		1.54 (0.04, 8.28)
Mir (2011) - neonatal	Pakistan	2004-2007	59	583		10.12 (7.79, 12.86)
Ray (2013)	USA	2009-2011	2442	57714		4.23 (4.07, 4.40)
Zhanel (2010)	Canada	2008	8	493		1.62 (0.70, 3.17)
CANWARD	Canada	2010-2012	38	1268		3.00 (2.13, 4.09)
CANWARD	Canada	2013-2016	46	1287		3.57 (2.63, 4.74)
SENTRY	USA	2015-2017	366	14836		2.47 (2.22, 2.73)
SENTRY	Europe	2015-2017	153	9396		1.63 (1.38, 1.91)
SENTRY	Asia Pacific	2015-2017	48	2148		2.23 (1.65, 2.95)
SENTRY	Latin America	2015-2017	11	1392		0.79 (0.40, 1.41)
Overall (I^2 = 65.05, p = 0.00)						3.05 (2.00, 4.62)
with estimated predictive interval						(0.83, 10.56)
Complicated SSTI						
Garau (2013)	Europe	2010-2011	32	1275		2.51 (1.72, 3.52)
Heizmann (2013)	Germany	2006-2011	1	711		0.14 (0.00, 0.78)
Heizmann (2013)	Spain-1	2006-2011	0	128		0.00 (0.00, 2.84)
Heizmann (2013)	France	2006-2011	0	122		0.00 (0.00, 2.98)
Heizmann (2013)	Spain-2	2006-2011	1	47		2.13 (0.05, 11.29)
Jääskeläinen (2013)	Finland, Sweden	2008-2011	16	483		3.31 (1.91, 5.32)
Jones (2003)	USA	2001	92	26233		0.35 (0.28, 0.43)
Jones (2003)	France	2001	224	23012		0.97 (0.85, 1.11)
Jones (2003)	Germany	2001	137	17205		0.80 (0.67, 0.94)
Jones (2003)	Italy	2001	25	6884		0.36 (0.24, 0.54)
Jones (2003)	Spain	2001	48	11764		0.41 (0.30, 0.54)
Li (2016)	China	2008-2013	2	198		1.01 (0.12, 3.60)
ECDC	Europe	2011-2012	4	462		0.87 (0.24, 2.20)
Overall (I^2 = 57.41, p = 0.00)						1.02 (0.48, 2.15)
with estimated predictive interval						(0.13, 7.42)

Figure 5. Prevalence of *Streptococcus agalactiae* in isolates from skin and soft tissue infections (SSTI).

Table 4
Streptococcus agalactiae as a percentage of urinary tract infection (UTI) isolates.

Setting[a]	Age group	Number of estimates included	Pooled % prevalence estimate (95% CI)	I^2 (p-value)
Community + hospital	All ages combined	57	1.09 (0.77–1.54); $\tau^2 = 0.94$	60.1% ($p < 0.01$)
Community (both sexes)	Overall (all ages combined)	30	1.61 (1.13–2.30); $\tau^2 = 0.64$	79.5% ($p < 0.01$)
	Infants (<4 months)	2	0.61 (0.38–1.00)	–
	Child	2	0.91 (0.86–0.96)	–
	Adult (all ages)	12	1.86 (1.05–3.25); $\tau^2 = 0.74$	78.7% ($p < 0.01$)
	Adult (elderly)[b]	4	1.63 (0.72–3.64); $\tau^2 = 0.35$	48.3% ($p < 0.01$)
Community (female)	All ages	12	1.51 (0.87–2.62); $\tau^2 = 0.75$	68.9% ($p < 0.01$)
	Adult (all ages)	8	1.66 (0.87–3.15); $\tau^2 = 0.56$	74.6% ($p < 0.01$)
	Adult (elderly)[b]	1	6.82 (1.43–18.9)	–
Hospital (non-specific + CAUTI)	All ages	27	0.73 (0.43–1.23); $\tau^2 = 1.04$	39.7% ($p < 0.01$)
Hospital (non-specific)	Overall (all ages combined)	19	0.99 (0.58–1.68); $\tau^2 = 0.74$	53.2% ($p < 0.01$)
	Infants (<4 months)	3	1.23 (0.72–2.12); $\tau^2 = 0.13$	–
	Child	4	1.09 (0.47–2.51); $\tau^2 = 0.47$	41.8% ($p < 0.01$)
	Adult	2	2.15 (2.12–2.18)	–
Hospital (CAUTI)	All ages	8	0.26 (0.24–0.29); $\tau^2 = 0.00$	0.0% ($p = 1.00$)

CI, confidence interval; CAUTI, catheter-associated UTI.
[a] Community UTI specimens either from GP/primary care/outpatient clinic or a hospital inpatient specimen within 48 h of admission; hospital (non-specific) UTI do not specifically exclude CAUTI; 3/6 CAUTI sources were intensive care units (ICU).
[b] Three quarters of community elderly adult settings were long-term care facilities (LTCF), including the setting for community female elderly adult UTIs.

Discussion

This study generated global estimates for the potential role of *S. agalactiae* (GBS) as a causative agent of a wide range of community and healthcare-associated infections. Overall, GBS was isolated from a small proportion (1%) of SSI and UTI, and a very small proportion (<0.5%) of RTI. However, GBS was implicated in noticeably higher proportions of SSI following caesarean section (3.5% overall, 9.7% of organ/space SSI), vascular surgery SSI (2.4%), SSTI (1.9%), and community UTI (1.6% overall). GBS also accounted for slightly higher proportions of SSI after orthopaedic (1.1%) and breast surgery (1.2%), which is of concern given current and projected volumes of these procedures (Kummerow et al., 2015; Kurtz et al., 2007) and the potential seriousness of prosthetic joint infections (Gundtoft et al., 2017). Estimates based on a small number of studies for eye and ear infections indicated a very low proportion of GBS among ocular infection isolates, and no GBS isolated from ear infections.

The relatively high proportion of caesarean section organ/space SSI attributable to GBS reflects the role of GBS as an important pathogen in maternal sepsis, causing 15–25% of bacteraemia in pregnancy and postpartum (Blanco et al., 1981; Drew et al., 2015; Knowles et al., 2015; Surgers et al., 2013). Studies of post-caesarean SSI suggest that up to 10% of caesarean sections had a subsequent SSI (Wilson et al., 2013; Aulakh et al., 2018; Griffiths et al., 2005).

Study/source	Country	Period	GBS	Isolates		Prevalence (95% CI)
UTI (infants <4mo)						
Greenhow (2014)	USA	2005-2011	4	823		0.49 (0.13, 1.24)
PHE	England	2015-2016	12	1793		0.67 (0.35, 1.17)
FE Model with no Heterogeneity						0.61 (0.38, 1.00)
UTI (children)						
PHE	England	2015-2016	1154	131269		0.88 (0.83, 0.93)
NZ	New Zealand	2014-2017	61	2060		2.96 (2.27, 3.79)
FE Model with no Heterogeneity						0.91 (0.86, 0.96)
UTI (all ages)						
Rodriguez Lopez (2005)	Spain	1992-2003	270	11350		2.38 (2.11, 2.68)
Andreu (2005)	Spain	2002	46	2724		1.69 (1.24, 2.25)
Guerreiro (2012)	Portugal	2010	32	1594		2.01 (1.38, 2.82)
Jodra (2006)	Spain	1997-2006	10	719		1.39 (0.67, 2.54)
Jodra (2006)	Spain	2007-2016	9	1340		0.67 (0.31, 1.27)
Karlowsky (2011)	Canada	2007-2009	45	1506		2.99 (2.19, 3.98)
Laupland (2007)	Canada	2004-2005 (inp.)	147	7608		1.93 (1.63, 2.27)
Kiffer (2007)	Brazil	2000-2003	122	37261		0.33 (0.27, 0.39)
Naber (2008)	Global	2003-2006	54	3018		1.79 (1.35, 2.33)
Laupland (2007)	Canada	2004-2005 (amb.)	869	31270		2.78 (2.60, 2.97)
Overall (I^2 = 92.77, p = 0.00)						1.55 (0.96, 2.49)
with estimated predictive interval						. (0.29, 7.72)
UTI (adults, all ages)						
Lee (2004)	Korea	2002	1	239		0.42 (0.01, 2.31)
Malmartel (2016)	France	2014	21	1125		1.87 (1.16, 2.84)
Hooton (2013)	USA	2002-2012	2	143		1.40 (0.17, 4.96)
Magliano (2012)	Italy	2008-2009	313	13820		2.26 (2.02, 2.53)
Lee (2011)	Korea	2008-2009	9	143		6.29 (2.92, 11.61)
Monsen (2014)	Sweden	1995-1998	6	887		0.68 (0.25, 1.47)
Kronenberg (2011)	Switzerland	2008-2009 (r)	6	388		1.55 (0.57, 3.34)
Kronenberg (2011)	Switzerland	2008-2009 (s)	6	357		1.68 (0.62, 3.62)
Matsumoto (2011)	Japan	2008	47	994		4.73 (3.49, 6.24)
NZ	New Zealand	2014-2017	777	11820		6.57 (6.13, 7.04)
PHE	England	2015-2016	23786	1331155		1.79 (1.76, 1.81)
Kazemier (2014)	Netherlands	2011-2013 (ABU preg)	0	255		0.00 (0.00, 1.44)
Overall (I^2 = 78.73, p = 0.00)						1.86 (1.05, 3.25)
with estimated predictive interval						. (0.25, 12.59)
UTI (adults, elderly)						
Hedin (2002)	Sweden	1998-1999 (LTCF, ABU)	3	55		5.45 (1.14, 15.12)
Brabazon (2012)	Ireland	2010	11	1169		0.94 (0.47, 1.68)
Brabazon (2012)	Ireland	2010 (LTCF)	5	963		0.52 (0.17, 1.21)
Laupland (2007)	Canada	2004-2005 (LTCF)	79	3907		2.02 (1.60, 2.51)
Overall (I^2 = 48.34, p = 0.00)						1.63 (0.72, 3.64)
with estimated predictive interval						. (0.07, 27.40)

0

Figure 6. Prevalence of *Streptococcus agalactiae* in isolates from community urinary tract infections (UTI).

| Study/source	Country	Period	GBS	Isolates		Prevalence (95% CI)
Catheter-associated UTI (all ages)						
Agodi (2013)	Italy	2012-2013	1	86		1.16 (0.03, 6.31)
CDC	USA	2011-2014	406	153805		0.26 (0.24, 0.29)
Choi (2016)	South Korea	2006-2012	15	4767		0.31 (0.18, 0.52)
ECDC	Spain	2008-2015	12	6708		0.18 (0.09, 0.31)
ENVIN-HELICS	Spain	2008-2016	9	4656		0.19 (0.09, 0.37)
Moulton (2017)	USA	2013	2	24		8.33 (1.03, 27.00)
PREZIES	Netherlands	2007-2017	5	1037		0.48 (0.16, 1.12)
Phu (2016)	Vietnam	2012-2013	0	22		0.00 (0.00, 15.44)
Overall (I^2 = 0.00, p = 1.00)						0.26 (0.24, 0.29)
with estimated predictive interval						. (0.23, 0.30)
UTI (infants <4mo)						
Bauserman (2013)	USA	1997-2010	18	836		2.15 (1.28, 3.38)
Hanna-Wakim (2015)	Lebanon	2001-2011	0	64		0.00 (0.00, 5.60)
PHE	England	2015-2016	102	10985		0.93 (0.76, 1.13)
FE Model with no Heterogeneity						1.01 (0.84, 1.21)
UTI (children)						
Hanna-Wakim (2015)	Lebanon	2001-2011	3	611		0.49 (0.10, 1.43)
NZ	New Zealand	2014-2017	29	958		3.03 (2.04, 4.32)
PHE	England	2015-2016	743	79360		0.94 (0.87, 1.01)
Zajazc-Spychala (2016)	Poland	2012-2013	0	51		0.00 (0.00, 6.98)
Overall (I^2 = 41.79, p = 0.00)						1.09 (0.47, 2.51)
with estimated predictive interval						. (0.03, 26.33)
UTI (all ages)						
Bouza (2001)	Europe	1999	3	186		1.61 (0.33, 4.64)
Bouza (2001)	Europe	2000	3	121		2.48 (0.51, 7.07)
ECDC	Europe	2011-2012	10	2168		0.46 (0.22, 0.85)
Hayami (2013)	Japan	2009-2010	8	387		2.07 (0.90, 4.03)
Jodra (2006)	Spain	1997-2006	14	2813		0.50 (0.27, 0.83)
Jodra (2006)	Spain	2007-2016	7	3292		0.21 (0.09, 0.44)
Karlowsky (2011)	Canada	2007-2009	7	1437		0.49 (0.20, 1.00)
PREZIES	Netherlands	2007-2017	4	434		0.92 (0.25, 2.34)
Sabra (2012)	Saudi Arabia	2010-2011	0	43		0.00 (0.00, 8.22)
Zhanel (2010)	Canada	2008	6	983		0.61 (0.22, 1.32)
Overall (I^2 = 28.84, p = 0.00)						0.69 (0.42, 1.13)
with estimated predictive interval						. (0.17, 2.76)
UTI (adults, all ages)						
NZ	New Zealand	2014-2017	523	9538		5.48 (5.03, 5.96)
PHE	England	2015-2016	19772	933125		2.12 (2.09, 2.15)
FE Model with no Heterogeneity						2.15 (2.12, 2.18)

0

Figure 7. Prevalence of *Streptococcus agalactiae* in isolates from healthcare-associated urinary tract infections (UTI).

Table 5
Streptococcus agalactiae as a percentage of respiratory tract infection (RTI) isolates.

Setting[a]	Age group	Number of estimates included	Pooled % prevalence estimate (95% CI)	I^2 (p-value)
Community + hospital	All ages combined	23	0.30 (0.17–0.52); $\tau^2 = 0.65$	17.1% (p < 0.01)
	Child	3	0.19 (0.03–1.32); $\tau^2 = 0.00$	–
	Adult (all ages)	1	0.00 (0.00–0.63)	–
Community	All ages combined	4	0.35 (0.19–0.63); $\tau^2 = 0.00$	0.00% (p = 1.00)
	Child	2	0.19 (0.03–1.36)	–
Hospital (non-specific + VAP)	All ages combined	17	0.27 (0.15–0.48); $\tau^2 = 0.59$	12.5% (p < 0.01)
Hospital (non-specific)	All ages combined	10	0.45 (0.23–0.88); $\tau^2 = 0.44$	11.6% (p < 0.01)
	Child	1	0.00 (0.00–24.7)	–
Hospital (VAP)	All ages combined	7	0.17 (0.07–0.39); $\tau^2 = 0.43$	13.9% (p < 0.01)
	Adult (all ages)	1	0.00 (0.00–0.63)	–

CI, confidence interval; VAP, ventilator-associated pneumonia.

[a] Community RTI specimens either from GP/primary care/outpatient clinic or a hospital inpatient specimen within 48 h of admission; hospital (non-specific) RTI do not specifically exclude VAP; 5/7 VAP settings were intensive care units (ICU).

Figure 8. Prevalence of *Streptococcus agalactiae* in isolates from respiratory tract infection.

PHE data implicated GBS in 5% of caesarean section SSI, corresponding to national estimates of approximately 850 cases (including 170 organ/space SSI) after 170 000 annual operations. It was also noted that the one study that reported a high prevalence of GBS in CAUTI isolates (8.33%, 95% CI 1.03–27.0%) was in a cohort of women who had undergone caesarean section (Moulton et al., 2017). The extent to which a common underlying mechanism of infection, such as epithelial exfoliation (Vornhagen et al., 2018), explains ascending infection leading to invasive GBS disease in pregnancy and also serious postpartum SSI and UTI remains to be determined. Commonly used and endorsed prophylaxis regimens (e.g. cefazolin) are generally effective against GBS, and it may be that utility of and compliance with recommendations needs be evaluated, including optimal timing of antibiotic administration. In future, measures to prevent neonatal GBS disease could have the additional clinical and cost benefit of preventing a significant proportion of maternal GBS disease (Kim et al., 2017; Vekemans et al., 2018).

A trend towards a higher prevalence of GBS by degree of invasiveness (from superficial to deep to organ/space) was also evident for orthopaedic, but not abdominal or cardiac SSI, the latter including donor site incisions. Reasons for these discrepancies, and for the relatively high prevalence of GBS in breast and vascular SSI, are unclear. Breast cancer as a risk factor for invasive GBS disease has been described in two population studies, but as an underlying disease rather than in relation to surgery (Farley et al., 1993; Jackson et al., 1995). GBS represented a smaller proportion of SSTI isolates in studies that focused on cSSTI (1.0%) compared with studies that did not focus on cSSTI (3.1%). This is the opposite of what might be expected given an increased risk of invasive GBS infection in patients with chronic underlying conditions (Sendi et al., 2008), and if GBS has a proclivity for invasive infection.

The mains strengths of this systematic review are its wide geographic scope and the inclusion of data from several large surveillance systems. Also, for SSI, common case definitions (based on CDC/NHSN criteria) were used by all but one of the included studies. The main limitations are heterogeneity in case definitions for the other types of infections, and heterogeneity and bias in sampling and laboratory methods. For example, in community and primary care settings, GBS is more likely to be implicated in the types of infection, e.g. cystitis, that are treated empirically, with testing reserved for recalcitrant, e.g. antimicrobial-resistant, infections that are less likely to be caused by GBS. Or, in settings where all urine samples are routinely tested, generic culture methods may not favour the identification of GBS. Both of these factors would underestimate the prevalence of GBS in UTIs. For wound and SSI we would expect GBS to be detected by routinely used non-selective culture methods, although the use of non-selective media could fail to detect GBS in wound infections such as perineal or groin or peri-anal abscesses where competing microflora can inhibit the growth of GBS in culture (El Aila et al., 2010; Gupta and Briski, 2004). An example of heterogeneity between studies is in the healthcare-associated UTI in children subgroup, where the higher prevalence of GBS in data from New Zealand may be related to the Auckland District Health Board providing most of the complex healthcare for New Zealand, including national paediatric care, meaning that this source of UTI data will encompass children with high dependency and significant co-morbidities.

Hooton et al. reported that the detection of GBS in midstream urine samples has poor positive predictive value for acute cystitis (using paired midstream-catheter urine samples from healthy premenopausal women) regardless of colony count threshold, although the number of GBS cystitis cases was very small (Hooton et al., 2013). Given that the majority of UTI studies reported on midstream urine samples, contamination by colonizing GBS would inflate the prevalence of GBS as a causative agent of UTI in the present meta-analysis. The misattribution of clinical infection to colonizing GBS would be more of an issue for superficial incisional, skin, respiratory, throat, and eye infections than for deep/organ/space infections, and correcting this bias would reduce GBS prevalence estimates for these types of infection towards zero.

Where the frequency of GBS was not originally reported in a published study, the authors' responses indicated that the actual frequency was zero vs. non-zero in similar proportions (10/22 zero vs. 12/22 non-zero). This suggests that the meta-analyses will not be biased towards over-reporting the prevalence of GBS. Publication bias is unlikely to affect the study findings because much of the data originated from surveillance systems and were purely descriptive. Some sources did not account for polymicrobial infections in their denominators, but this would not affect GBS as a proportion of the total number of isolates unless there was preferential reporting of particular microorganisms or if GBS in polymicrobial flora were more likely to be colonizing rather than infecting; no differences in GBS prevalence by type of denominator were detected. Some of the surgical categories encompassed a wide range of procedures within which GBS may have represented a varying proportion of SSI, e.g. colorectal and bowel operations within the abdominal surgery category, and coronary artery bypass graft with or without donor incision surveillance in the cardiac surgery category. Overall, superficial SSIs are less likely to be captured by surveillance systems owing to inconsistent use of community post-discharge surveillance, whereas deep and organ-space infections frequently result in re-admission to hospital.

In conclusion, although GBS accounts for a relatively small proportion of SSI and UTI, the absolute numbers of patients with infections due to GBS will be large. Accurate estimates of GBS prevalence, particularly for infections such as UTI, which are often treated empirically, require studies designed specifically to detect GBS, using selective media in unbiased samples of clinical cases. The relatively high prevalence of GBS in caesarean section SSI suggests a need for further research with a view to evaluating current practices concerning surgical antibiotic prophylaxis administration (choice, timing of delivery of agents) and the assessment of treatment regimens to ensure use of an agent that covers GBS.

Ethical approval

Not required.

Conflict of interest

The authors declare no competing interests.

One-sentence summary

Worldwide, group B *Streptococcus* is implicated in a small proportion (1–2%) of surgical site, skin and soft tissue, and urinary tract infections, a very small proportion (<0.5%) of respiratory tract infections, but a substantial proportion (10%) of invasive surgical site infections following caesarean section.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.ijid.2019.04.017.

References

Agodi A, Auxilia F, Barchitta M, Brusaferro S, D'Alessandro D, Grillo OC, et al. Trends, risk factors and outcomes of healthcare-associated infections within the Italian network SPIN-UTI. J Hosp Infect 2013;84(1):52–8.

Allegranzi B, Bagheri Nejad S, Combescure C, Graafmans W, Attar H, Donaldson L, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet 2011;377(January (9761)):228–41.

Alvarez Lerma F, Palomar Martinez M, Olaechea Astigarraga P, Insausti Ordenana J, Bermejo Fraile B, Cerda Cerda E. National surveillance study of hospital-acquired infections in intensive care units. Report on the year 2002. Medicina Intensiva 2005;29(1):1–12.

Andreu A, Alos JI, Gobernado M, Marco F, De La R, Garcia-Rodriguez JA. Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: a nationwide surveillance study. Enfermedades Infecciosas y Microbiologia Clinica 2005;23(1):4–9.

Aulakh A, Idoko P, Anderson ST, Graham W. Caesarean section wound infections and antibiotic use: a retrospective case-series in a tertiary referral hospital in The Gambia. Trop Doct 2018;48(July (3)):192–9.

Badia JM, Casey AL, Petrosillo N, Hudson PM, Mitchell SA, Crosby C. Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. J Hosp Infect 2017;96(May (1)):1–15.

Ballard MS, Schonheyder HC, Knudsen JD, Lyytikainen O, Dryden M, Kennedy KJ, et al. The changing epidemiology of group B streptococcus bloodstream infection: a multi-national population-based assessment. Infect Dis (Lond) 2016;48(5):386–91.

Ba-Saddik IA, Munibari AA, Alhilali AM, Ismail SM, Murshed FM, Coulter JB, et al. Prevalence of Group A beta-haemolytic Streptococcus isolated from children with acute pharyngotonsillitis in Aden, Yemen. Trop Med Int Health 2014;19 (April (4)):431–9.

Bauserman MS, Laughon MM, Hornik CP, Smith PB, Benjamin Jr DK, Clark RH, et al. Group B Streptococcus and Escherichia coli infections in the intensive care nursery in the era of intrapartum antibiotic prophylaxis. Pediatr Infect Dis J 2013;32(March (3)):208–12.

Behzadnia S, Davoudi A, Rezai MS, Ahangarkani F. Nosocomial infections in pediatric population and antibiotic resistance of the causative organisms in north of iran. Iran Red Crescent Med J 2014;16(February (2))e14562.

Bianchi-Jassir F, Seale AC, Kohli-Lynch M, Lawn JE, Baker CJ, Bartlett L, et al. Preterm birth associated with group B streptococcus maternal colonization worldwide: systematic review and meta-analyses. Clin Infect Dis 2017;65(November (Suppl_2)):S133–42.

Bingen E, Cohen R, Jourenkova N, Gehanno P. Epidemiologic study of conjunctivitis-otitis syndrome. Pediatr Infect Dis J 2005;24(August (8)):731–2.

Bjornsdottir ES, Martins ER, Erlendsdottir H, Haraldsson G, Melo-Cristino J, Kristinsson KG, et al. Changing epidemiology of group B streptococcal infections among adults in Iceland: 1975-2014. Clin Microbiol Infect 2016;22(April (4)):379 e9–e16.

Blanco JD, Gibbs RS, Castaneda YS. Bacteremia in obstetrics: clinical course. Obstet Gynecol 1981;58(November (5)):621–5.

Bouza E, San Juan R, Munoz P, Voss A, Kluytmans J. A European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). European Study Group on Nosocomial Infections. Clin Microbiol Infect 2001a;7(October (10)):523–31.

Bouza E, San Juan R, Munoz P, Voss A, Kluytmans J, Co-operative Group of the European Study Group on Nosocomial I. A European perspective on nosocomial urinary tract infections II. Report on incidence, clinical characteristics and outcome (ESGNI-004 study). European Study Group on Nosocomial Infection. Clin Microbiol Infect. 2001b;7(October (10)):532–42.

Brabazon E, Carton M, Dornikova G, Bedford D. Epidemiology and resistance patterns in urinary pathogens from long-term care facilities and GP populations. Ir Med J 2012;105(June (6)):177–80.

Camuset G, Picot S, Jaubert J, Borgherini G, Ferdynus C, Foucher A, et al. Invasive Group B streptococcal disease in non-pregnant adults, Reunion Island, 2011. Int J Infect Dis 2015;35(June):46–50.

Canadian Antimicrobial Resistance Alliance (CARA). Canadian ward surveillance study (CANWARD). 2016 Available from: http://www.can-r.com. [cited 07/ 2017].

Chaiwarith R, Jullaket W, Bunchoo M, Nuntachit N, Sirisanthana T, Supparatpinyo K. Streptococcus agalactiae in adults at Chiang Mai University Hospital: a retrospective study. BMC Infect Dis 2011;25(May (11)):149.

Choi JY, Kwak YG, Yoo H, Lee SO, Kim HB, Han SH, et al. Trends in the distribution and antimicrobial susceptibility of causative pathogens of device-associated infection in Korean intensive care units from 2006 to 2013: results from the Korean Nosocomial Infections Surveillance System (KONIS). J Hosp Infect 2016;92(April (4)):363–71.

Ciani O, Grassi D, Tarricone R. An economic perspective on urinary tract infection: the "costs of resignation". Clin Drug Investig 2013;33(April (4)):255–61.

Cossin S, Malavaud S, Jarno P, Giard M, L'Heriteau F, Simon L, et al. Surgical site infection after valvular or coronary artery bypass surgery: 2008-2011 French SSI national ISO-RAISIN surveillance. J Hosp Infect 2015;91(November (3)):225–30.

Deptula A, Trejnowska E, Dubiel G, Zukowski M, Misiewska-Kaczur A, Ozorowski T, et al. Prevalence of healthcare-associated infections in Polish adult intensive care units: summary data from the ECDC European Point Prevalence Survey of Hospital-associated Infections and Antimicrobial Use in Poland 2012-2014. J Hosp Infect 2017;96(2):145–50.

Drew RJ, Fonseca-Kelly Z, Eogan M. A retrospective audit of clinically significant maternal bacteraemia in a specialist maternity hospital from 2001 to 2014. Infect Dis Obstet Gynecol 2015;2015:518562.

El Aila NA, Tency I, Claeys G, Saerens B, Cools P, Verstraelen H, et al. Comparison of different sampling techniques and of different culture methods for detection of group B streptococcus carriage in pregnant women. BMC Infect Dis 2010;29 (September (10)):285.

Elgohari S, Wilson J, Saei A, Sheridan EA, Lamagni T. Impact of national policies on the microbial aetiology of surgical site infections in acute NHS hospitals in England: analysis of trends between 2000 and 2013 using multi-centre prospective cohort data. Epidemiol Infect 2017;145(5):957–69.

El-Kholy A, Saied T, Gaber M, Younan MA, Haleim MMA, El-Sayed H, et al. Device-associated nosocomial infection rates in intensive care units at Cairo University hospitals: first step toward initiating surveillance programs in a resource-limited country. Am J Infect Control 2012;40(6):e216–20.

European Centre for Disease Prevention and Control (ECDC). Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. Stockholm: ECDC; 2013.

European Centre for Disease Prevention and Control (ECDC). Surgical site infections. Annual Epidemiological Report for 2015. Stockholm: ECDC; 2016.

European Centre for Disease Prevention and Control (ECDC). Healthcare-associated infections acquired in intensive care units. Annual Epidemiological Report for 2015. Stockholm: ECDC; 2017.

Falagas ME, Rosmarakis ES, Avramopoulos I, Vakalis N. Streptococcus agalactiae infections in non-pregnant adults: single center experience of a growing clinical problem. Med Sci Monit 2006;12(November (11))CR447-51.

Farley MM, Harvey RC, Stull T, Smith JD, Schuchat A, Wenger JD, et al. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med 1993;328(June (25)):1807–11.

Fong ZV, McMillan MT, Marchegiani G, Sahora K, Malleo G, De P, et al. Discordance between perioperative antibiotic treatment and wound infection cultures in patients undergoing pancreaticoduodenectomy: a multicenter 5-year study. Gastroenterology. 2015;148(4 Suppl. 1):S1111.

Garau J, Ostermann H, Medina J, Avila M, McBride K, Blasi F. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect 2013;19 (September (9)):E377–85.

Goh PP, Shamala R, Chandamalar S, Tai XY, National Eye Database Study G. Contact lens—related corneal ulcer: a two-year review. Med J Malaysia 2010;65(June (Suppl. A)):120–3.

Greenhow TL, Hung YY, Herz AM, Losada E, Pantell RH. The changing epidemiology of serious bacterial infections in young infants. Pediatr Infect Dis J 2014;33(June (6)):595–9.

Griffiths J, Demianczuk N, Cordoviz M, Joffe AM. Surgical site infection following elective Caesarian section: a case-control study of postdischarge surveillance. J Obstet Gynaecol Can 2005;27(April (4)):340–4.

Guerreiro A, Duarte A, Ramalheiro A. Community-acquired urinary tract infection: prevalence and resistence-a 1 year experience. Clin Microbiol Infect 2012;18:800.

Gundtoft PH, Pedersen AB, Varnum C, Overgaard S. Increased mortality after prosthetic joint infection in primary THA. Clin Orthop Relat Res 2017;475 (November (11)):2623–31.

Gupta C, Briski LE. Comparison of two culture media and three sampling techniques for sensitive and rapid screening of vaginal colonization by group B streptococcus in pregnant women. J Clin Microbiol 2004;42(September (9)):3975–7.

Hall J, Adams NH, Bartlett L, Seale AC, Lamagni T, Bianchi-Jassir F, et al. Maternal disease with group B streptococcus and serotype distribution worldwide: systematic review and meta-analyses. Clin Infect Dis 2017;65(November (Suppl_2)):S112–24.

Hanna BC, McMullan R, Gallagher G, Hedderwick S. The epidemiology of peritonsillar abscess disease in Northern Ireland. J Infect 2006;52(April (4)):247–53.

Hanna-Wakim RH, Ghanem ST, El Helou MW, Khafaja SA, Shaker RA, Hassan SA, et al. Epidemiology and characteristics of urinary tract infections in children and adolescents. Front Cell Infect Microbiol 2015;5(May):45.

Hayami H, Takahashi S, Kiyota H, Ishikawa K, Yasuda M, Arakawa S, et al. Nationwide surveillance of bacterial pathogens from patients with acute uncomplicated cystitis in Japan. Int J Antimicrob Agents 2013;42:S61.

Heath PT, Culley FJ, Jones CE, Kampmann B, Le Doare K, Nunes MC, et al. Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis. Lancet Infect Dis 2017;17(July (7)):e223–34.

Hedin K, Petersson C, Wideback K, Kahlmeter G, Molstad S. Asymptomatic bacteriuria in a population of elderly in municipal institutional care. Scand J Prim Health Care 2002;20(September (3)):166–8.

Heizmann WR, Dupont H, Montravers P, Guirao X, Eckmann C, Bassetti M, et al. Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies. J Antimicrob Chemother 2013;68(July (Suppl. 2)):ii45–55.

Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med 2013;369(November (20)):1883–91.

Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36(June (5)):309–32.

Huang PY, Lee MH, Yang CC, Leu HS. Group B streptococcal bacteremia in non-pregnant adults. J Microbiol Immunol Infect 2006;39(June (3)):237–41.

Husson MO, Pierreti A, Quelquejay J, Vaneecloo FM, Courcol RJ, Vincent C. Bacteriological epidemiological study of acute otitis media in infants observed at home in Nord Pas-de-Calais area. Pathologie Biologie 2001;49(10):789–93.

IntHout J, Ioannidis JP, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open 2016;6(July (7))e010247.

Jaaskelainen IH, Hagberg L, From J, Schyman T, Lehtola L, Jarvinen A. Treatment of complicated skin and skin structure infections in areas with low incidence of antibiotic resistance-a retrospective population based study from Finland and Sweden. Clin Microbiol Infect 2016;22(April (4)):383 e1–e10.

Jackson LA, Hilsdon R, Farley MM, Harrison LH, Reingold AL, Plikaytis BD, et al. Risk factors for group B streptococcal disease in adults. Ann Intern Med 1995;123 (September (6)):415–20.

Jeong SJ, Ann HW, Kim JK, Choi H, Kim CO, Han SH, et al. Incidence and risk factors for surgical site infection after gastric surgery: a multicenter prospective cohort study. Infect Chemother 2013;45(December (4)):422–30.

Jodra VM, Diaz-Agero P, Sainz de los Terreros S, Saa RCM, Dacosta B, et al. Results of the Spanish national nosocomial infection surveillance network (VICONOS) for surgery patients from January 1997 through December 2003. Am J Infect Control 2006;34(3):134–41.

Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003;22(October (4)):406–19.

Karlowsky JA, Lagace-Wiens PR, Simner PJ, DeCorby MR, Adam HJ, Walkty A, et al. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Antimicrob Agents Chemother 2011;55 (July (7)):3169–75.

Kazemier B, Koningstein F, Schneeberger C, Ott A, Bossuyt P, De M, et al. Prevalence and risk factors for asymptomatic bacteriuria in low risk pregnant women, the ASB screening study. Am J Obstet Gynecol 2014;210(1 Suppl. 1):S247–8.

Kennedy EH, Greene MT, Saint S. Estimating hospital costs of catheter-associated urinary tract infection. J Hosp Med 2013;8(September (9)):519–22.

Kerneis S, Plainvert C, Barnier JP, Tazi A, Dmytruk N, Gislain B, et al. Clinical and microbiological features associated with group B Streptococcus bone and joint infections, France 2004-2014. Eur J Clin Microbiol Infect Dis 2017;36(September (9)):1679–84.

Kiffer CR, Mendes C, Oplustil CP, Sampaio JL. Antibiotic resistance and trend of urinary pathogens in general outpatients from a major urban city. Int Braz J Urol 2007;33(January–February (1))42–8 discussion 9.

Kim ES, Kim HB, Song KH, Kim YK, Kim HH, Jin HY, et al. Prospective nationwide surveillance of surgical site infections after gastric surgery and risk factor analysis in the Korean Nosocomial Infections Surveillance System (KONIS). Infect Control Hosp Epidemiol 2012;33(June (6)):572–80.

Kim SY, Nguyen C, Russell LB, Tomczyk S, Abdul-Hakeem F, Schrag SJ, et al. Cost-effectiveness of a potential group B streptococcal vaccine for pregnant women in the United States. Vaccine 2017;35(October (45)):6238–47.

Knowles SJ, O'Sullivan NP, Meenan AM, Hanniffy R, Robson M. Maternal sepsis incidence, aetiology and outcome for mother and fetus: a prospective study. BJOG 2015;122(April (5)):663–71.

Kohli-Lynch M, Russell NJ, Seale AC, Dangor Z, Tann CJ, Baker CJ, et al. neurodevelopmental impairment in children after group B streptococcal disease worldwide: systematic review and meta-analyses. Clin Infect Dis 2017;65(November (Suppl_2)):S190–9.

Kronenberg A, Koenig S, Droz S, Muhlemann K. Active surveillance of antibiotic resistance prevalence in urinary tract and skin infections in the outpatient setting. Clin Microbiol Infect 2011;17(December (12)):1845–51.

Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 2015;150(January (1)):9–16.

Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007;89(April (4)):780–5.

Lamagni TL, Keshishian C, Efstratiou A, Guy R, Henderson KL, Broughton K, et al. Emerging trends in the epidemiology of invasive group B streptococcal disease in England and Wales, 1991-2010. Clin Infect Dis 2013;57(September (5)):682–8.

Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB. Community-onset urinary tract infections: a population-based assessment. Infection 2007;35(June (3)):150–3.

Le Doare K, Heath PT. An overview of global GBS epidemiology. Vaccine 2013;31 (August (Suppl. 4)):D7–12.

Le Doare K, O'Driscoll M, Turner K, Seedat F, Russell NJ, Seale AC, et al. Intrapartum antibiotic chemoprophylaxis policies for the prevention of group B streptococcal disease worldwide: systematic review. Clin Infect Dis 2017;65(November (Suppl_2)):S143–51.

Lee SJ, Lee SD, Cho IR, Sim BS, Lee JG, Kim CS, et al. Antimicrobial susceptibility of uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2002. Int J Antimicrob Agents 2004;24 (September (Suppl. 1)):S61–4.

Lee SJ, Lee DS, Choe HS, Shim BS, Kim CS, Kim ME, et al. Antimicrobial resistance in community-acquired urinary tract infections: results from the Korean Antimicrobial Resistance Monitoring System. J Infect Chemother 2011;17(June (3)):440–6.

Lefebvre N, Forestier E, Mohseni-Zadeh M, Remy V, Lesens O, Kuhnert C, et al. Invasive *Streptococcus agalactiae* infections in non-pregnant adults. Med Mal Infect 2007;37(December (12)):796–801.

Li X, Chen Y, Gao W, Ouyang W, Wei J, Wen Z. Epidemiology and outcomes of complicated skin and soft tissue infections among inpatients in southern China from 2008 to 2013. PLoS One 2016;11(2)e0149960.

Madrid L, Seale AC, Kohli-Lynch M, Edmond KM, Lawn JE, Heath PT, et al. Infant group B streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses. Clin Infect Dis 2017;65(November (Suppl_2)):S160–S172.

Magliano E, Grazioli V, Deflorio L, Leuci AI, Mattina R, Romano P, et al. Gender and age-dependent etiology of community-acquired urinary tract infections. Sci World J 2012;2012:349597.

Malmartel A, Ghasarossian C. Epidemiology of urinary tract infections, bacterial species and resistances in primary care in France. Eur J Clin Microbiol Infect Dis 2016;35(March (3)):447–51.

Mannien J, van der Zeeuw AE, Wille JC, van den Hof S. Validation of surgical site infection surveillance in the Netherlands. Infect Control Hosp Epidemiol 2007;28(January (1)):36–41.

Matsumoto T, Hamasuna R, Ishikawa K, Takahashi S, Yasuda M, Hayami H, et al. Nationwide survey of antibacterial activity against clinical isolates from urinary tract infections in Japan (2008). Int J Antimicrob Agents 2011;37(March (3)):210–8.

Merritt C, Haran JP, Mintzer J, Stricker J, Merchant RC. All purulence is local - epidemiology and management of skin and soft tissue infections in three urban emergency departments. BMC Emerg Med 2013;13(1):26.

Miller D. Update on the epidemiology and antibiotic resistance of ocular infections. Middle East Afr J Ophthalmol 2017;24(January–March (1)):30–42.

Mir F, Tikmani SS, Shakoor S, Warraich HJ, Sultana S, Ali SA, et al. Incidence and etiology of omphalitis in Pakistan: a community-based cohort study. J Infect Dev Ctries 2011;5(December (12)):828–33.

Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007;57(January (1)):7–13.

Monsen TJ, Holm SE, Ferry BM, Ferry SA. Mecillinam resistance and outcome of pivmecillinam treatment in uncomplicated lower urinary tract infection in women. APMIS 2014;122(April (4)):317–23.

Montravers P, Bassetti M, Dupont H, Eckmann C, Heizmann WR, Guirao X, et al. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother 2013;68(July (Suppl. 2)):ii15–24.

Morris AJ, Panting AL, Roberts SA, Shuker C, Merry AF. A new surgical site infection improvement programme for New Zealand: early progress. N Z Med J 2015;128 (May (1414)):51–9.

Morrissey I, Burnett R, Viljoen L, Robbins M. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002. J Infect 2004;49(August (2)):109–14.

Moulton L, Lachiewicz M, Liu X, Goje O. Catheter-associated urinary tract infection (CAUTI) after term cesarean delivery: incidence and risk factors at a multi-center academic institution. J Matern Fetal Neonatal Med 2017;1–6.

Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008;54 (November (5)):1164–75.

Nagashima K, Noma H, Furukawa TA. Prediction intervals for random-effects meta-analysis: a confidence distribution approach. Stat Methods Med Res 2018; (January)962280218773520.

Nizami SQ, Bhutta ZA, Hasan R. Incidence of acute respiratory infections in children 2 months to 5 years of age in periurban communities in Karachi, Pakistan. J Pak Med Assoc 2006;56(April (4)):163–7.

Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 2014;72(1):39.

Owens CD, Stoessel K. Surgical site infections: epidemiology, microbiology and prevention. J Hosp Infect 2008;70(November (Suppl. 2)):3–10.

Phu VD, Wertheim HFL, Larsson M, Nadjm B, Dinh QD, Nilsson LE, et al. Burden of hospital acquired infections and antimicrobial use in Vietnamese adult intensive care units. PLoS One 2016;11(1)0147544.

Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. BMC Infect Dis 2013;13(May (1)):252.

Rennert-May E, Bush K, Vickers D, Smith S. Use of a provincial surveillance system to characterize postoperative surgical site infections after primary hip and knee arthroplasty in Alberta, Canada. Am J Infect Control 2016;44(11):1310–4.

Rodriguez LFC, Franco-Alvarez de L, Gordillo URM, Ibarra G, et al. Microorganisms isolated from outpatient urine samples and antimicrobial susceptibility over a 12-year period. Rev Esp Quimioter 2005;18(2):159–67.

Russell NJ, Seale AC, O'Driscoll M, O'Sullivan C, Bianchi-Jassir F, Gonzalez-Guarin J, et al. Maternal colonization with group B streptococcus and serotype distribution worldwide: systematic review and meta-analyses. Clin Infect Dis 2017a;65(November (Suppl_2)):S100–11.

Russell NJ, Seale AC, O'Sullivan C, Le Doare K, Heath PT, Lawn JE, et al. Risk of early-onset neonatal group B streptococcal disease with maternal colonization worldwide: systematic review and meta-analyses. Clin Infect Dis 2017b;65 (November (Suppl_2)):S152–9.

Sabra SM, Abdel-Fattah MM. Epidemiological and microbiological profile of nosocomial infection in Taif hospitals, KSA (2010-2011). World J Med Sci 2012;7(1):1–9.

Santé publique France. Surveillance des infections du site opératoire dans les établissements de santé français - Résultats 2015. Saint-Maurice; 2016.

Seale AC, Blencowe H, Bianchi-Jassir F, Embleton N, Bassat Q, Ordi J, et al. Stillbirth with group B streptococcus disease worldwide: systematic review and meta-analyses. Clin Infect Dis 2017a;65(November (Suppl_2)):S125–32.

Seale AC, Bianchi-Jassir F, Russell NJ, Kohli-Lynch M, Tann CJ, Hall J, et al. Estimates of the burden of group B streptococcal disease worldwide for pregnant women, stillbirths, and children. Clin Infect Dis 2017b;65(November (Suppl_2)):S200–19.

Sendi P, Johansson L, Norrby-Teglund A. Invasive group B Streptococcal disease in non-pregnant adults: a review with emphasis on skin and soft-tissue infections. Infection 2008;36(March (2)):100–11.

Skoff TH, Farley MM, Petit S, Craig AS, Schaffner W, Gershman K, et al. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. Clin Infect Dis 2009;49(July (1)):85–92.

Song KH, Kim ES, Kim YK, Jin HY, Jeong SY, Kwak YG, et al. Differences in the risk factors for surgical site infection between total hip arthroplasty and total knee

arthroplasty in the Korean Nosocomial Infections Surveillance System (KONIS). Infect Control Hosp Epidemiol 2012;33(11):1086–93.

Sorlozano A, Jimenez-Pacheco A, de Dios Luna Del Castillo J, Sampedro A, Martinez-Brocal A, Miranda-Casas C, et al. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study. Am J Infect Control 2014;42(October (10)):1033–8.

Stapleton F, Keay LJ, Sanfilippo PG, Katiyar S, Edwards KP, Naduvilath T. Relationship between climate, disease severity, and causative organism for contact lens-associated microbial keratitis in Australia. Am J Ophthalmol 2007;144 (November (5)):690–8.

Surgers L, Valin N, Carbonne B, Bingen E, Lalande V, Pacanowski J, et al. Evolving microbiological epidemiology and high fetal mortality in 135 cases of bacteremia during pregnancy and postpartum. Eur J Clin Microbiol Infect Dis 2013;32(January (1)):107–13.

Tann CJ, Martinello KA, Sadoo S, Lawn JE, Seale AC, Vega-Poblete M, et al. Neonatal encephalopathy with group B streptococcal disease worldwide: systematic review, investigator group datasets, and meta-analysis. Clin Infect Dis 2017;65 (November (Suppl_2)):S173–89.

Truong DT, Bui MT, Cavanagh HD. Epidemiology and outcome of microbial keratitis: private university versus urban public hospital care. Eye Contact Lens 2016; (October).

Varotto F, Di M, Azzaro R, Bellissima P, Amato R, Fogliani V, et al. An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacil-lin/tazobactam, ceftazidime and ceftriaxone. J Chemother 2001;13(4):413–23.

Vekemans J, Moorthy V, Friede M, Alderson MR, Sobanjo-Ter Meulen A, Baker CJ, et al. Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics. Vaccine 2018;(February).

Vornhagen J, Armistead B, Santana-Ufret V, Gendrin C, Merillat S, Coleman M, et al. Group B streptococcus exploits vaginal epithelial exfoliation for ascending infection. J Clin Invest 2018;128(May (5)):1985–99.

Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011-2014. Infect Control Hosp Epidemiol 2016;37(11):1288–301.

Wilson J, Wloch C, Saei A, McDougall C, Harrington P, Charlett A, et al. Inter-hospital comparison of rates of surgical site infection following caesarean section delivery: evaluation of a multicentre surveillance study. J Hosp Infect 2013;84 (May (1)):44–51.

Worth LJ, Epi GD, Bull AL, Spelman T, Brett J, Richards MJ. Diminishing surgical site infections in Australia: time trends in infection rates, pathogens and antimicrobial resistance using a comprehensive Victorian Surveillance Pro-gram, 2002-2013. Infect Control Hosp Epidemiol 2015;36(4):409–16.

Zajac-Spychala O, Wachowiak J, Pieczonka A, Siewiera K, Fraczkiewicz J, Kalwak K, et al. Bacterial infections in pediatric hematopoietic stem cell transplantation recipients: incidence, epidemiology, and spectrum of pathogens: report of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation. Transpl Infect Dis 2016;18(October (5)):690–8.

Zhanel GG, DeCorby M, Adam H, Mulvey MR, McCracken M, Lagace-Wiens P, et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother 2010;54(November (11)):4684–93.

Zhou Y, Dendukuri N. Statistics for quantifying heterogeneity in univariate and bivariate meta-analyses of binary data: the case of meta-analyses of diagnostic accuracy. Stat Med 2014;33(July (16)):2701–17.